Analysis and Development of Phenomenological Models for the Relative Biological Effectiveness in Proton Therapy by Rørvik, Eivind
Eivind Rørvik
Analysis and Development of




Thesis for the degree of Philosophiae Doctor (PhD)
University of Bergen, Norway
at the University of Bergen
Avhandling for graden philosophiae doctor (ph.d )
ved Universitetet i ergen
.
2017
Dato for disputas: 1111
Analysis and Development of 
Phenomenological Models for the 
Relative Biological Effectiveness 
in Proton Therapy
Eivind Rørvik
Thesis for the de ree of P il i  Doctor (PhD)
Date of defense: 23.08.2019
The material in this publication is covered by the provisions of the Copyright Act.
Print:     Skipnes Kommunikasjon / University of Bergen
© Copyright Eivind Rørvik
Name:        Eivind Rørvik
Title: Analysis and Development of Phenomenological Models for the Relative Biological
Effectiveness in Proton Therapy

















«Å leve går an 
uten Brann 
og uten bauekorps og vannkopper på Haukeland. 
Eg e glad i godt ver 
og torre kler, 
men likevel så sønger eg så ofte så eg kan: 
 
Eg ve te Bergen, ve te Bergen med det samme. 
Der har eg det så fisken i vannet: 
Vått og kaldt, og breiflabb overalt.» 
 
- Knutsen og Ludvigsen 
 4
Scientific environment 
The PhD study is part of the project «3D microdosimetry and studies of the Relative 
Biological Effectiveness (RBE) in proton- and carbon ion therapy» funded by the 
Bergen Research Foundation. The project includes both development of biological 
models and detector development and is organised by project leader Kristian Smeland 
Ytre-Hauge within the subatomic physics group at Department of Physics and 
Technology at the University of Bergen.  
The study in this work was aided by dose planners, medical physicists and oncologists 
at the Department of Medical Physics and Oncology at Haukeland University Hospital 
(HUH). The department consists of a radiotherapy clinic with active research, 
performed by researchers/experts within radiation therapy and general medical physics. 
HUH is planning to build a proton therapy facility within five years. 
Parts of this work were also done in collaboration with Monte Carlo experts at Centro 
Nazionale di Adroterapia Oncologica (CNAO), an operational proton and carbon ion 
therapy center in Pavia, Italy. One month was spent in Pavia, providing a clinical 
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Proton therapy is undergoing a rapid development making it increasingly popular as a 
treatment of cancer. Protons interact differently with the tissue compared to 
conventional radiation therapy with photons, resulting in a more beneficial dose 
distribution with greater dose conformation. The radiation quality is also different for 
protons and photons, as the ionisation density, often quantified by the linear energy 
transfer (LET), is higher for protons than for photons. Irradiation experiments on cells 
and animal models have shown that protons are slightly more effective in producing 
biological damage than photons. This difference in biological response is quantified by 
the relative biological effectiveness (RBE), which aid the comparison of the dose 
deposition from the two modalities and enables transferal of established clinical 
protocols from photon therapy to proton therapy. A conservative and constant RBE of 
1.1 is used in proton therapy clinics, even though experiments have shown that the RBE 
can be both higher and lower, varying with different biological and physical quantities, 
including the LET value. 
Phenomenological RBE models try to determine the various RBE dependencies from 
large experimental databases of cell irradiation experiments. In this work, existing 
phenomenological models were analysed and explored in a coherent manner: All 
models were parameterised and described by functions of the maximum RBE (RBEmax) 
and minimum RBE (RBEmin), the two model functions that make every model unique. 
The models were implemented in the FLUKA Monte Carlo code and used in estimation 
of the RBE and RBE-weighted dose for multiple patient plans and relevant dose 
parameters. The models were also analysed and compared regarding the underlying 
similarities and differences, which forms the basis for the unique definitions of RBEmax 
and RBEmin of each model. A new phenomenological RBE model was proposed, 
introducing the full LET spectrum as an input parameter for phenomenological models. 
Statistical methods were used to test whether a non-linear LET dependency of RBEmax 
would give a superior description of the experimental data compared to using the 
established linear dependency of the dose-averaged LET (LETd).  Further, we analysed 
the LETd dependency of RBEmin in a two-step regression analysis, as the RBEmin 
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function is most commonly assumed to be constant for all LETd values. Specifically, 
we analysed how restriction on the minimum dose of the underlying experimental 
database influenced RBEmin. 
The estimation of the RBE and the RBE-weighted dose from the various models 
differed significantly. The largest deviations were seen for organs at risk (OAR) with 
low fractionation sensitivity ((α/β)x) and high LET. These variations are a result of the 
distributions of (α/β)x values and LETd values in the experimental databases, the 
assumptions for RBEmax and RBEmin and regression analysis method. The full LET 
spectrum was found to give a better representation of the experimental database 
included in our analysis. Regression weighted to the reported experimental 
uncertainties showed that a non-linear function (quartic function) gave a better fit to 
the data than a linear function. The RBEmin function was found to vary with the LETd 
value if dose constraints were added to the experimental database. By restricting the 
minimum dose in the database to be 1 Gy or lower, the analysis gave a non-negligible 
linear LETd dependency, while higher minimum doses indicated that the dependency 
is constant. 
The deviations in the estimated RBE from the models can be traced back to the model 
differences in the database construction, the model assumptions and the regression 
techniques. Various methods were used in this thesis to develop novel models by 
reanalysing published data, such as construction of model databases with strict 
constraints, using the pure dose-survival data instead of only  α and β values, statistical 
analysis of model assumptions, applying multiple regression techniques and 
recognition of the LET spectrum as a relevant input parameter. Together, these 
techniques could minimise the researcher bias and make more accurate RBE models, 
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1.  Introduction 
Cancer is a group of diseases where the genetic code of a cell has mutated, leading to 
an abnormal cell growth with the potential of also invading other regions of the body. 
From being an almost certain death 50 years ago, the development of better diagnostics 
and treatment through cancer research have changed the face of cancer. Overall 
survival rates for cancer diseases have been steadily increasing since the 1970s 
(Quaresma, Coleman, and Rachet 2015). A study assumed that approximately 5 million 
have avoided death to cancer in Europe over the three last decades (Malvezzi et al. 
2018). Still, at what might seem contradictive, cancer was the most common cause of 
death in Norway in 2017 for the first time (FHI 2018). It is estimated that over 30 000 
patients every year are diagnosed with cancer in Norway, and the number is increasing.  
Radiation therapy is one of three main modalities used for cancer treatment, together 
with surgery and chemotherapy. A study reported that around half of all cancer patients 
in Australia would benefit from radiation therapy (Barton et al. 2014). The principle of 
radiation therapy is that ionising radiation should target and damage the unwanted 
cancer cells, while sparing the healthy normal cells. If the treatment is successful, the 
cells are not able to proliferate, and the cancer cells will eventually die.  
As more people are cured from cancer, an increasing amount of people are also living 
with complications and late reactions induced by the radiation therapy. The damage to 
the healthy tissue should be minimised to avoid harming the patient. There exists 
therefore a strong rationale for decreasing the dose to the non-cancerous tissue of 
patients, as one assumes there is a correlation between higher dose and increased 
normal tissue complication probability (NTCP). 
Today, conventional external radiotherapy is delivered by linear accelerators, creating 
high energetic X-rays that penetrate through the body, harming cells on the way 
through the patient. Radiotherapy have been aided heavily by modern technology and 
software development over the last decades. The radiotherapy technology has taken 
incremental steps to optimise the treatment delivery; from simple single field plans all 
the way to complicated Volumetric Modulated Arc Therapy (VMAT) plans. Every step 
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has increased the overall dose conformity, targeting tumour tissue and sparing healthy 
tissue. However, the steady increase in dose conformity through technological 
developments is about to converge towards a physical limit, governed by the spatial 
dose distribution of photons and electrons. For many sites, organs at risk (OAR) still 
limit the dose that can safely be administered to the target volume. Conventional 
photon treatment may deliver an unacceptable large dose to OAR, due to the physical 
dose distribution of photon beams.  
If the patient is treated with protons instead of photons, the dose conformity in radiation 
therapy can still be improved. A proton beam has a significantly different depth dose 
curve compared to photons. High energetic X-rays and gamma-rays have a depth dose 
distribution with a maximum a few centimetres into the tissue and thereafter decreasing 
with increasing depth. Protons on the contrary have a relative flat dose in the entrance 
and a maximum towards the end of their path, known as the Bragg peak. The location 
of the Bragg peak is determined by the energy of the proton beam. This energy can be 
modulated to create a spread out Bragg peak (SOBP), which cover the full extent of 
the tumour with a uniform dose (Wilson 1946).  
The number of patients treated with proton therapy is increasing at an exponential rate, 
with a more than 170 000 patients treated worldwide (Jermann 2018). In general, the 
better dose conformity of protons compared to conventional radiation lowers the dose 
to OARs and other normal tissue, which will lower the NTCP for many patients 
(Widder et al. 2016). However, the increased dose conformity is not the only benefit 
from protons.   
The ionisation density of protons is higher than for photons, meaning that ions are more 
effective in the inactivation processes of cancer cells. If photons and protons deliver 
the same physical dose, the latter will be more biological effective, e.g. inactivate a 
higher fraction of cells. This difference is not negligible and must be accounted for in 
proton therapy. The relative biological effectiveness (RBE) is introduced as a scaling 
factor for the physical proton dose. The quantity is able to estimate the comparable 
photon doses to proton doses, consequently aiding the transferral of knowledge gained 
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from photon therapy to proton therapy. Based on experiments with animals in the 
1970s, the RBE of protons was set to be 1.1, i.e. protons are assumed to be 10% more 
effective than photons for the same physical dose. The conservative value is still used 
today in proton therapy clinics, even though experiments have shown that the RBE can 
be higher and varies with the fraction dose, tissue type and the ionisation density. 
Multiple dose planning studies of patient plans have shown that a potential variable 
RBE could lead to an increased dose to OARs compared to the doses reported by the 
clinically used treatment planning system, which only calculate the dose using an RBE 
of 1.1. These studies estimated RBE from various RBE models. Phenomenological 
RBE models are a group of models that rely and focus on experimental data. The model 
creators try to find relationships between the input and output quantities of experiments 
without modelling specific subcellular effects, contrary to mechanistic models.  
The goal of this study was to analyse and compare established phenomenological RBE 
models for proton therapy, by exploring their similarities and experimental basis. We 
also wanted to investigate existing experimental data found in the literature to develop 
novel phenomenological models. The creation of better and more precise RBE models 
could improve the dose determination of proton therapy and make safer and better 





2. Radiation physics 
Ionising radiation is radiation that carries high enough energy to ionise material, i.e. 
removing electrons from atom and molecules. The treatment dose in radiotherapy is 
traditionally quantified using the absorbed dose, D, representing the amount of energy 
deposited by the radiation per unit mass of the tissue: 
where ΔE is the energy (Joules) and Δm is the mass of the tissue (kg) where the energy 
is deposited. The absorbed dose is a physical measurable quantity, measured in units 
of Gray (Gy). Conventional radiation therapy is performed by neutral photons without 
mass, whereas proton therapy is performed with massive charged particles. The 
primary goal of radiation therapy is to damage the DNA molecules inside the cancer 
cells, either directly by  the initial particles/radiation (direct action) or subsequently by 
free radicals produced by the radiation (indirect action). The biology is further 
described in section 3, while an overview of the physical interactions between protons 
and tissue are given in this section. 
2.1 Proton Interactions 
The protons are accelerated to relativistic velocities before entering the patient. They  
will primarily interact with the patient’s tissue through three different mechanisms: 
Stopping, scattering and nuclear interactions. Bremsstrahlung is also theoretical 
possible, however, at therapeutic proton energies the effect is negligible (Newhauser 
and Zhang 2015). 
When the protons traverse the tissue, electrons will absorb parts of the kinetic energy 
through electromagnetic force interactions, resulting in ionisations and excitations. As 
a result, the kinetic energy of the protons is transferred to the matter and the protons 
are slowed down. This inelastic force imparted on the protons from the matter is termed 
“stopping power” and defined as the loss of energy per unit of length. The force is 
dependent on multiple parameters, such as the material composition and electron 
density of the tissue and the velocity of the protons. The stopping power for different 





charged particles and materials can be calculated by the Bethe-Bloch formula (Bethe 
1930, Bloch 1933a, 1933b) or experimental tables (Lühr et al. 2012, Greilich et al. 
2010, ICRU 1993). The protons will ionise the impacted molecules and create 
secondary electrons (delta ray), transferring energy from the protons to the material. 
This is described more in depth in section 2.3. 
In addition to being stopped by the electrons in the tissue, protons also interact with the 
electromagnetic field of the nuclei. If the protons come too close to the nucleus, the 
protons may change their trajectory, introducing a lateral deflection in the proton track. 
The elastic coulomb interactions between the protons and the nuclei are dependent on 
the charge of the nuclei, which can be analytical calculated by the Molière’s theory 
(Molière 1948, Bethe 1953). Heavier elements in the tissue will increase the magnitude 
of scattering. Beam absorbers should therefore be created of material with low Z, to 
decrease the spread of the pencil beam (Brennsæter 2015). 
The electromagnetic interactions with the electrons and the nuclei of the tissue material 
are the dominating modes of interaction, however, in rare instances, protons are also 
able to overcome the Coulomb barrier and interact directly with the particles within the 
nucleus. These nuclear interactions can result in secondary particles through creation 
of heavier elements and recoil particles from the tissue, which themselves can ionise 
the tissue (Paganetti 2002). Similar to the ionised electrons, these secondary particles 
can be highly energetic and interact with tissue far away from the central axis of the 
protons, by creating delta rays or ion clusters. Besides secondary protons, helium ions 
are the most usual secondary particles seen in proton therapy. These are primarily 
created in the entrance, when the kinetic energy of the proton beam is high (Grassberger 
and Paganetti 2011, Paganetti 2002).  
The three different interactions describe the energy transfer on a subatomic scale 
between the proton and the tissue. All these interactions can be regarded as random and 
stochastic, even though the probability of an interaction is dependent on the proton 
energy, electron density and nuclei composition in the tissue (Newhauser and Zhang 
2015). The stochastic nature of every interaction makes it impossible to predict the fate 
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of a single proton, and every proton track and local dose deposition is unique. A 
schematic example of a short proton track is shown in the diagram in Figure 1A. 
2.2 Macroscopic dose distrubution 
In a clinical beam, billions of protons are accelerated and used in the irradiation of the 
tumour. The beam consists of many independent track structures. This leads to a stable 
and reproducible dose distribution, following the mathematical laws of large numbers 
(Metropolis and Ulam 1949). A macroscopic dose distribution of a monoenergetic 
proton beam deposited in a water phantom is illustrated by isodose curves in the lateral 
direction in Figure 1B and the dose intensity along the central axis in Figure 1C. 
The ionisation density of the traversing protons increases towards the end of the range, 
before the protons come to a halt. This results in the distinctive peak at the end of the 
depth dose distribution. The initial energy spread in the proton beam combined with 
the stochastic nature of the proton stopping (i.e. range straggling) determine the width 
of the Bragg peak. The scattering effect is significant in proton therapy compared to 
heavier ions, and narrow pencil beams will broaden and become widened at the end of 
range, as seen by the expanded isodose curves in Figure 1B. 
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Figure 1: A: An example of the track structure in a nanometric scale of an 
accelerated proton traversing matter. Each point represents one interaction 
between the traversing proton or secondary particles and the atoms in the 
tissue. Although a single-track structure is chaotic, many protons leads to a 
stable dose distribution, as shown in the macroscopic diagrams in B and C. 
B: Arbitrary isodose curves, illustrating the result of lateral scattering, i.e. a 
broadening of the lateral dose with depth. C: The depth dose distribution 
along central axis, where the dose is relatively constant until the distinctive 
Bragg peak. Inspired by ICRU report 16 (1970). 
2.3 Linear energy transfer  
Even though two different radiation modalities, e.g. 6 MV photons and protons, deposit 
the same physical macroscopic dose within the tissue, the pattern of dose deposition 
can be different because of differences in the ionisation density and track structure. The 
term radiation quality is used to describe these physical properties, normally quantified 
by the linear energy transfer (LET) of the radiation (ICRU 1970). LET is defined as 
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the infinitesimal amount of mean energy transferred from the proton to the tissue 
locally (dE in keV) per infinitesimal part of the proton track (dl in μm): 
The energy transferred to the tissue locally from a proton could maximum equal the 
energy lost by the proton. If the energy of the incoming proton is high enough, the 
collision could create delta ray electrons, which could deposit their energy relative far 
away from the origin. A restricted LET (LETΔ) definition is used to focus on the energy 
deposited in the vicinity of the proton track, which exclude the transfer to electrons 
with energies above a maximum transfer energy Δ. If all collisions are included in the 
definition, the quantity is termed unrestricted LET (LET∞). As no energy is excluded, 
LET∞ will then equal the stopping power of the proton. There is little difference 
between LETΔ and LET∞ in the clinical energy range for protons and relevant 
secondary particles (Grzanka 2014).  
The LET is dependent on the energy of the traversing proton, as the stopping power 
varies with the velocity of the proton. As shown in Figure 2, the LET value decreases 
with increasing energy and ranges between 0.2 and 84 keV/μm in the clinical relevant 
energy range (ICRU 1993, Wilkens, J J and Oelfke 2004). By integrating the proton 
stopping power from zero to the full proton energy, the residual range of the proton can 
be estimated, e.g. by the continuous slowing down approximation (CSDA) (Fano 
1953). As shown, the LET value increases with decreasing CSDA, i.e. closer to the 







Figure 2: The unrestricted LET value of protons in water as a function of the 
energy of the proton. The x-axis on the top quantifies the remaining range of 
the protons in water, estimated with the continuous slowing down 
approximation (CSDA). The curve was obtained using the Libamtrack online 
calculator (Greilich et al. 2010). 
The LET value also varies significantly the type of particle traversing the tissue, as 
heavier particles such as helium and carbon ions have a higher electrical charge, leading 
to a greater stopping power. Furthermore, the stopping power is dependent on the 
electron density and the composition of the tissue material with different materials 
leading to a change in the LET value of the accelerated protons (Bernard Gottschalk 
2011). In conventional photon therapy, the dose is reported by the dose to water (Dw) 
instead of the dose to tissue. Similarly, radiation quality is primarily reported by the 
LET to water (LETw), independent on the tissue the particles are traversing through 
(Wilkens, Jan J. and Oelfke 2004, Paganetti 2009).  
For an infinitesimal volume, the dose from monoenergetic protons can be calculated 
from the fluence and the LET value of those protons: 
where  is the proton fluence and  is the tissue density. As the equation states, fewer 
protons are needed to deposit a prescribed dose for a beam consisting of high LET 
    , 
	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protons, compared to a beam consisting of low LET protons. Equation 	 can also 
be used to describe the dose to water, by finding the LETw from tables and using the 
water density () instead of the specific tissue density. 
2.3.1 Linear energy transfer spectrum 
In a clinical setting, the treatment beam within the patient do not consist of only 
monoenergetic protons, even for pristine pencil beams. As the mean energy decreases 
with increasing depth, the energy spread increases and the stochastic nature of stopping 
and scattering creates a beam with a range of energies. In addition, heavier secondary 
particles are produced by nuclear interactions and “pollutes” the proton beam 
(Grassberger and Paganetti 2011). The radiation quality can therefore be described by 
a dose weighted spectrum from protons of different LET values (d(L)) at every spatial 
location, instead of a single quantity:  
where L is the LET value, D(L) is the absolute dose yielded by particles with LET 
value L and D is the total dose given to the specific location. The dose weighted LET 
spectrum (d(L)) is defined such that the sum of all dose compositions is normalised to 
1 (ICRU 1970).  
Examples of dose weighted spectra are shown in Figure 3, where the LET spectrum is 
depicted in the entrance and at the Bragg peak. As shown, the spectrum is narrow in 
the entrance, while at the end of the range the spectrum is shifted towards higher values 
and broaden out. The composition of the beam gets increasingly complex for a 
Spread-out Bragg Peak (SOBP) beam with multiple initial energies, and even more 
complex for treatments with many fields, often termed a “mixed treatment field” (Lam 















Figure 3: A depth dose curve of a monoenergetic proton beam of 116 MeV 
in a water phantom shown in Figure A. The LET spectrum at the entrance is 
shown in B and the spectrum at the Bragg peak is shown in C, both positions 
illustrated in A. The depth dose curve and the LET spectra is created by the 
author with the FLUKA Monte Carlo code. 
Alternatively, the LET spectrum can be track (or fluence, f(L)) weighted , where the 
LET values are distributed relative to the number of particles traversing the tissue 
instead of the dose deposited by them. For our work, we only focus on the dose 
weighted LET spectrum, hereafter referred to as the LET spectrum. For simplicity, it 
is common to only use the dose averaged LET (LETd) value, a single quantity, instead 
of the full LET spectrum (Polster et al. 2015):  
Generally, the LETd value increases with increasing treatment depth, and the highest 
LETd values are found distal to the Bragg peak at the distal dose falloff. In a practical 
clinical setting, only a limited range of LETd values between 0 and 20 keV/μm are seen 












(Paganetti 2014). The typical LETd values in the middle of the SOBP, i.e. middle of the 
tumour, are 2-3 keV/μm. 
Alternative approaches to describe the radiation quality are the energy spectrum (Belli, 
Campa, and Ermolli 1997) or microdosimetric quantities such as lineal energy (l) or 
specific energy (z) (Loncol et al. 1994, Inaniwa et al. 2010) or the number of proton 





3. Radiation biology 
The purpose of radiation therapy is to heal cancer patients by sterilising and stopping 
the proliferation of the cancer cells. Studies have shown that the DNA within the 
nucleus is the molecule target which inactivates the cancer cells, as well as normal cells 
(Kaplan and Moses 1964). The ionisation process might lead to single strand breaks 
(SSB) or double strand breaks (DSB) of the DNA molecules. Most SSB are repaired 
immediately or at most a few hours later by biological processes (Hall and Giaccia 
2006). Incomplete repair of the damaged DNA might induce cell death, inhibiting the 
proliferating of cells. Generally, normal cells have lower division rates and better repair 
mechanisms compared to cancer cells, making them more resistant to radiation. In very 
rare instances the repair can be performed incorrectly and introduce a gene mutation 
which will be inherited by the daughter cells.  
As mentioned in section 2, the DNA can be damaged either directly by the proton beam 
or secondary electrons, or indirectly by free radicals created in the water around the 
DNA molecule (Joiner and Kogel 2016). Direct action creates more DSBs than indirect 
action and is more prominent in proton therapy compared to conventional therapy, as 
the local ionisation density of a proton beam is higher than for conventional photon 
radiation (Hirayama et al. 2009). 
The biological effects of radiation can be quantified with respect to different endpoints. 
At the cellular level, endpoints such as e.g. cellular survival, induction of radiosensitive 
proteins or DSBs, can be measured in cells radiated in vitro (Tommasino and Durante 
2015). Examples of endpoints for mice and rats irradiated in vivo  are early skin damage 
or crypt regeneration (Paganetti et al. 2002). However, clinically the primary and most 
important endpoints are the tumour control and a variety of normal tissue 
complications, which forms the basis for the clinical treatment protocols (Hall and 
Giaccia 2006). These are, however, more complex and difficult to measure, requiring 
and large clinical trials to be determined.  
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3.1 The linear-quadratic model 
The linear quadratic model (LQ-model) is a general dose response model which can 
describe the effect of radiation on multiple endpoints, both clinical and pre-clinical. To 
describe the survival fraction of cells irradiated in vitro, the model is defined as: 
where S is the fraction of cells surviving the radiation,  and  are the absolute 
number of surviving radiated and non-radiated reference cells and α and β are the 
LQ-model parameters. The model parameters are found by regression fitting to 
experimental data. Even though the model coefficients do not have a direct 
interpretation, the parameters can be coupled to the repair mechanisms of the cells. The 
first term of the exponential function in Equation 	
 describes unrepairable lethal 
damage, while the second term describes the repairable non-lethal damage. The ratio 
between the parameters (α/β), is commonly used to describe the fractionation 
sensitivity of different tissues and organs, as it is possible to extract the ratio from 
clinical endpoints, not only cell survival data.  The LQ-model is illustrated in Figure 4 
by two survival curves drawn using LQ-model regressions. The LQ model can be 
expanded to consider other effects that cannot be described by only two parameters. 
These effects include hyper sensitivity at low doses, linear effects at high doses, 
hypoxia, time dependencies and repopulation of the cells.  
3.2 Relative Biological Effectiveness 
By moving from photon therapy to proton therapy, the radiation quality changes, as 
described in Section 2.3. If the same amount of physical dose is given with photon and 
proton therapy, the latter will normally have higher effect, i.e. in a cell experiment the 
proton radiation would have inactivated a higher fraction of the cells (Paganetti 2014).  
 






The variations in biological effect for the same physical dose is described by the 
relative biological effectiveness (RBE), a scaling factor defined as: 
where , and - are the absorbed physical doses deposited by the reference photon 
and proton radiation, respectively. The RBE can be found by calculating the ratio of 
the dose levels for a specific endpoint, where both modalities are isoeffective. The most 
common endpoint measured by RBE experiments is cell survival fraction from in vitro 
irradiation, which also has become the basis for most RBE models. Mathematically, 
the survival fraction for both radiation modalities equals each other: 
where  &-+ and  , are the survival fractions of proton and photon irradiations, 
respectively. 
 
Figure 4: Schematic dose response curves of V79 hamster cells, irradiated 
with monoenergetic protons (α = 0.469 Gy-1 and β = 0.043 Gy-2) and with 
X-rays (α = 0.129 Gy-1 and β = 0.046 Gy-2) as reference radiation. The data 
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In vitro and in vivo experiments have shown that the RBE is variable and dependent on 
the measured biological endpoint, cell type, dose and radiation quality. The effect of 
selected endpoint is visualised in Figure 4. The scientific community, however, agreed 
in the 1970s that the proton RBE can be regarded as constant and settled on a general 
value of 1.1 as for the RBE (RBE1.1). Proton therapy clinics around the world have 
adapted this ratio in their protocols (Paganetti 2015). The assumption of 1.1 was 
adapted as a conservative number, even though experimental data have shown that the 
effect can be higher and is variable within a treatment field (Paganetti 2014).  
The RBE can then be multiplied with the physical proton dose to achieve the 
RBE-weighted dose (or sometimes termed biological dose), which is the dose quantity 
that is used and reported in clinics:  
To distinguish the difference from physical dose, the unit Gy(RBE) is used for 
RBE-weighted dose (Durante 2014). The most distinct variation in RBE and 
RBE-weighted dose is seen along the treatment depth, as qualitatively illustrated by the 
spread-out Bragg peak (SOBP) example in Figure 5. 
 
Figure 5: An example of a physical depth dose distribution for a SOBP, found 
by Monte Carlo simulations. The RBE-weighted dose is plotted above the 
physical dose, indicating the higher effectiveness for protons over photons, 
both corresponding to the left axis. The variable RBE value is shown by the 
 89:  - ; ./, 	<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points and the dashed curve. The lines between the points are only for 
guidance. As seen, the RBE is therefore not constant but increasing with 
depth in this example. Data extracted from Wouters et al. (2015) and Polster 
et al. (2015). 
The increased RBE with increasing depth is especially an issue for the organs at risk 
(OARs) distal to the target volume. This increased biological dose to OARs may 
increase the normal tissue complication probability (NTCP) of a patient treatment, even 
though the dose constraints are met with the RBE1.1 proton therapy plan (Jones 2016).  
3.3 Biological modelling of protons 
Better understanding of the proton RBE can give more precise treatment and ultimately 
a reduction in treatment complications. RBE modelling for protons is therefore a 
subject of high interest, and multiple models have been developed in the recent years. 
3.3.1 RBE models in literature 
RBE models found in literature can be divided into three major groups: 
Phenomenological models, plan-based models and mechanistic models.  
Phenomenological models try to describe the relationship of measurable empirical 
quantities (Belli, Campa, and Ermolli 1997, Wilkens, J J and Oelfke 2004, Tilly et al. 
2005, Chen and Ahmad 2012, Carabe et al. 2012, Wedenberg, Lind, and Hårdemark 
2013, Jones 2015a, 2015b, McNamara, Schuemann, and Paganetti 2015, Mairani et al. 
2017, Peeler et al. 2016). The models do not include any information or assumptions 
of cells on a subcellular level. Instead, the models rely on measurable input and output 
variables of cell irradiation experiments, typically the LETd and = and > of 
experiments. The model creators then assume appropriate dependencies for the model 
functions with free fitting parameters and perform regression analysis to the data to 
determine the parameters. This is covered in depth by this thesis. 
Plan-based models were developed as an alternative to the phenomenological and 
mechanistic models and are not directly based on cell experiments (Frese et al. 2011, 
Unkelbach et al. 2016). The term “plan-based model" is made to make the distinction 
that the model is made based on information from treatment plans, such as dose and 
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LETd distributions. Instead of being based on empirical cell data, the model creators 
assumed that the average RBE inside the target volume is 1.1, while the variable model 
functions are normalised to this.  
The last group of models are fundamentally different from the other two kind of 
models, as mechanistic models aim to model the biological effects on a microscopic 
scale within the cells, not only assuming and calculating relationship between 
experimental variables (Scholz et al. 1997, Hawkins 1994, Carlson et al. 2008, Cunha 
et al. 2017, McMahon et al. 2017). The microscopic dose distribution will give rise to 
lesions and local events within the nucleus, such as double strand breaks (DSB), which 
are estimated by the models. These events are quantified and used in the estimation of 
overall cell survival. 
The radiosensitivity of the cells is also known to vary with the oxygen level, as hypoxic 
cells are normally more radioresistant, both for photon and proton radiation (Hall and 
Giaccia 2006). Specialised models that incorporate the oxygen enhancement ratio 
(OER) have been developed (Durante 2014), which include the spatial oxygen level as 
input data. The developed proton RBE models do not consider effects of hypoxia.  
3.3.2 Mathematical model functions 
The RBE can be coupled with the LQ-model by inserting the mathematical description 
of the LQ-model of the proton and photon irradiation, as given in Equation 	
, into 
Equation 	: 
where Dp is the physical proton dose, αx and βx are the LQ-parameters of the photon 
radiation, is the physical proton dose and the = and > values are the LQ-parameters 
of the proton radiation. This equation can be solved for Dx and inserted into the 
definition of RBE, as given in Equation 	: 
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The RBE of the proton beam is then only a function of the proton dose and the 
LQ-model parameters. As a general rule, the RBE is highest at low doses and decreases 
with increasing dose. By evaluating the equation at the proton dose extremes, we 
achieve two equations for RBE values for either very low doses (RBEmax) or high doses 
(RBEmin):  
As seen, the extremes are simply the ratios (or square root of the ratio) of the LQ-model 
parameters of the photon and proton radiation. Equation 	L can be reformulated with 
respect to RBEmax and RBEmin:  
where = >M ,, equivalent to =, >,M , is the treatment fractionation sensitivity of the 
reference radiation.  
In principle, all phenomenological proton RBE models created up to this date can be 
parametrised into describing the two RBE extrema, even though the models are derived 
and modelled from different principles. The models will differ in how RBEmax and 
RBEmin are defined and on which input parameters the models are made dependent. It 
should be mentioned that some models quantify the = and > model parameters instead 
of RBEmax and RBEmin, however, these are closely linked to each other by Equation 
	N. One generic example for both RBEmax and RBEmin are given in Figure 6, where 
the equations are made linearly dependent on the LETd value. For a specific dose value, 
the RBE is found between these two lines, depending on both the dose deposited and 
the LETd values of the protons. 
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Figure 6: An illustration of two model functions for RBEmax and RBEmin where 
the RBEmax always is greater than RBEmin. For a specific physical fraction 
dose, the resulting RBE is found somewhere in between the two extreme 
functions.   
3.3.3 RBE dependencies 
The variable RBE models for proton therapy can be made dependent on three major 
parameters: The physical proton dose per fraction, radiation quality and tissue type 
(Paganetti 2014). The dose dependency is covered by the dose input in Equation 	Z, 
as RBEmax and RBEmin are independent on the fraction dose.  
An example of the variation in RBE with radiation quality can be seen in Figure 7 for 
one cell line. The steepness of the curves increases with increasing LETd value. 
Therefore, a proton beam with a higher LETd value will reach a chosen survival fraction 
at a lower dose compared to a beam with a lower LETd. This means that the RBE is 
positive dependent on the LETd value.  It is therefore typical to incorporate the increase 
in RBE with increasing LETd in RBE models, at least for the RBEmax, as illustrated in 
the generic example of Figure 6. 
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Figure 7: Schematic dose response curves of irradiated U87 cells, irradiated 
with monoenergetic protons with the noted LETd values or with X-rays as 
reference radiation. The α and β data originates from Chaudhary et al. 
(2014). 
The RBE also varies with different tissue types and cell lines. Survival curves for five 
cell lines irradiated with approximately the same LETd value are shown in Figure 8A, 
with the LETd dependency of RBEmax of the cell lines shown in Figure 8B. The large 
variation between the cell lines, advocates the inclusion of a tissue dependency in RBE 
models. For modelling proposes, the tissue or cell line is commonly represented by the 
(α/β)x value. It has been shown both analytically and experimentally, that RBEmax is 
inversely dependent on the (α/β)x value (Hawkins 1994, Wedenberg, Lind, and 
Hårdemark 2013).    
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Figure 8: Cell survival curves of five different cell lines, irradiated with 
monoenergetic protons with approximately 20 keV/μm (A). The RBEmax of the 
same cell lines relative to the LETd value of the experiments. The lines are 
only shown for guidance. The lines in A corresponds to the points in the 
middle of figure B. Data from Belli et al. (1998) and Belli et al. (2000). 
3.3.4 Mixed field radiation 
As described in section 2.3.1, a clinical beam does not consist of only monoenergetic 
protons of a single energy, a fact that needs to be taken into consideration when RBE 
models are created. To simplify the calculation of the RBE from the protons with a 
wide range of energies and LET values, the LETd of the total beam is most commonly 
used as input. This is mathematically correct if the biological weighting functions are 
linear, thus the model functions can be simplified to be LETd dependent: 
and 
where a, b, c and d are model constants, determined by the model creators (Paganetti 
2018, Paganetti et al. 2019a). Models with a linear LET dependency enables estimation 
of the RBE based only on the dose and LETd distributions. The estimation of RBE and 
RBE-weighted dose with the help of Equations (3.9) and (3.10) can be performed 
 ./RS,  [ I \ (3.9)
 ./RWX  ] I  (3.10)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subsequent to the dose calculation, a method termed offline calculation (Polster et al. 
2015). 
Equations (3.9) and (3.10) do, however, only approximate the correct RBE if the LET 
dependency of the model functions are linear. The approach of using LETd as a 
parameter might induce increased uncertainty in the RBE estimates, as some 
information about the radiation quality of the beam is lost when averaging the spectrum 
(Grassberger and Paganetti 2011, Inaniwa et al. 2015). If we assume that the LET 
dependency is non-linear, the equations need to be generalised. The RBE from a mixed 
field can be regarded as the dose weighted sum of individual RBE components, as 
earlier showed by Lam (1987). The formula for the mixed RBE can be parameterised 
into: 
where ^_ is a LET dependent biological weighting function and _ is the dose 
weighted LET spectrum. As shown by Kanai et al. (1997) and others, the general 
formula can be separated into the extreme RBE functions: 
and 
where ^S,_ and ^`a_ are the LET dependent biological weighting functions. It 
can be shown that Equations (3.9) and (3.10) are specific versions of Equations (3.12) 
and (3.13) if the biological weighting functions ^S,_ and ^`a_ are linear 
dependent on the LET value. If a model includes a biological weighting function with 
a non-linear LET dependency, these equations are obligatory. The RBE estimation then 
requires the whole LET spectrum as input. This further requires the LET spectrum to 
be found for every spatial location, if the RBE where to be calculated offline. 
Alternatively, Equations (3.12) and (3.13) can be estimated during the dose calculation, 
referred to as online calculation of the RBE-weighted dose (Polster et al. 2015). In 
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online calculations the RBE model need to be implemented into the software before 
the dose calculation is performed.  
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4. Thesis Objective 
The overall objective of this thesis was to investigate and improve phenomenological 
modelling of RBE for proton therapy. This comprised of analysis of existing models, 
methodology and available experimental data, as well as development of a new 
phenomenological RBE model. The specific objectives of each paper are given in the 
following.  
Paper I:  
 To review the published phenomenological and plan-based RBE models and 
compare their underlying experimental background and dependencies.  
 To create a general formalism for the RBE models and implement them into MC 
based architecture with a comparison of the resulting RBE-weighted doses to 
clinical cases. 
Paper II: 
 To investigate the LET dependency of RBE of cell survival experiments and 
test if a non-linear dependency will give a better representation of the existing 
data than a linear dependency.  
 To formulate a tissue dependent phenomenological model based on the LET 
spectrum as a parameter for the radiation quality. 
Paper III: 
 To aid the creation of RBE models by extracting more data from published 
experimental data. 







5. Materials and Methods 
5.1 Creation of RBE models from experimental data 
Based on previously published models, we devised a standardised routine for creation 
of phenomenological RBE models for proton therapy, as summarised in the flowchart 
in Figure 9. All models were made from an experimental database, normally gathered 
from a literature search with one or several inclusion and exclusion criteria (Figure 9, 
Box 1a). Some model creators modified and standardised the database before the fitting 
(Figure 9, Box 1b). The decision on dependencies of the model functions were 
formulated by the model creators before fitting, often as an educated guess based on 
the experimental database or inspired by previous publications (Figure 9, Box 2). The 
fitting of the functions to the database is done by regression to the database (Figure 9, 
Box 3) and the coefficients are numerically determined (Figure 9, Box 4). 
 
Figure 9: Flow chart of the creation of phenomenological RBE models based 
on the LQ-model formalism. The green parallelograms describe the input and 
output, the blue rectangles the calculation processes and the yellow hexagon 
describe regression preparations. 
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5.1.1 Experimental database 
For Papers II and III, we collected all proton cell survival experiments performed and 
published up to the time of writing the manuscripts. The extensive literature search was 
primarily based on the comprehensive database included in the review paper by 
Paganetti (2014), and complemented by more recent publications.  
For both these studies, we only analysed monoenergetic experiments, excluding cells 
irradiated with an SOBP beam or laser accelerated protons. In Paper II, all LETd values 
were allowed, while experiments above 20 keV/μm were excluded in Paper III. The 
model developed in Paper II was configured for a wide range of cell types, however, 
experiments with very high (α/β)x values (above 25 Gy) were excluded. Only late 
responding cells were analysed in Paper III, therefore the exclusion criterium was set 
to be maximum 5 Gy. 
From the included experiments, we extracted the reported LETd values. Further, the 
reported LQ-model parameter values were used in Paper II, while for Paper III, we 
extracted the dose/survival data points from all relevant experiments and refitted the 
LQ-model to the data points. The refitting was only done for the proton experiments, 
while the reference photon experiments were kept the same. The database in Paper III 
was further used as a basis to construct multiple restricted databases, with constraints 
on the minimum dose followed by refitting of the LQ-model. 
After extracting the data from the experiments in Paper II and III, we updated the 
databases (Figure 9, Box 1b). First, we adjusted for different radiation qualities of the 
reference radiation by calculating the relative LETd* (Paganetti 2014, Mairani et al. 
2016b). We also found the RBEmax and RBEmin of every experiment and determined 
the uncertainty of these quantities. The errors were found by using Gauss error 
propagation principle from the values and uncertainties in =, >, =, and >,. The origins 
of the uncertainties in =, >, =, and >, differs from publication to publication, however, 
most studies only report the uncertainties found from the regression analysis of the data 
points.  
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We did not create a new model or estimate the trend in RBEmax and RBEmin in Paper I 
for a specific database. For this study, we found all phenomenological models for the 
proton RBE published to this date. We further explored all the experimental databases 
used in the models and compared these to each other, with respect to their LETd and 
(α/β)x distributions. We also refitted some of the model functions to the model 
databases, to check the consequence of excluding outliers from the database.  
5.1.2 Model assumptions 
In Paper II, we fitted multiple potential functions for the RBEmax to the defined database 
to test the linearity assumption of RBE models. We assumed that the experiments were 
performed with monoenergetic beams, such that the beam only consisted of protons 
with a LET value equal to the reported LETd value. The cell response of the experiment 
corresponded to the specific LET value _, and the effect of monoenergetic protons can 
be extrapolated to a mixed field beam with multiple energies. Based on this assumption, 
we created a biological weighting function (^cTd_) based on Equation (3.12, which 
can be determined by regression to the monoenergetic database: 
where [e, [H, [f, [g and [h are coefficents determined by the regression analysis. The 
higher order terms were excluded from the regression when fitting the lower order 
polynomials. The function is inversely dependent on the (α/β)x value, similar to other 
modern models (Wedenberg, Lind, and Hårdemark 2013). 
In the creation of the model(s) in Paper II, we assumed that the RBEmin is constant and 
equal to 1 for all LETd values, which is the most common assumption for RBEmin in 
phenomenological RBE models (Wedenberg, Lind, and Hårdemark 2013, Chen and 
Ahmad 2012, Wilkens, J J and Oelfke 2004). This assumption was tested in Paper III, 
by introducing a linear function with only the first order coefficient c as a free fitting 
parameter: 
where c was found from linear regression to each of the restricted database. Only 
RBEmin was estimated in Paper III, not RBEmax. 
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5.1.3 Regression analysis 
In both Paper II and Paper III, the RBEmax and RBEmin functions were found by 
unweighted and weighted regression. For the latter, the inverse of the uncertainty of 
RBEmax and RBEmin were used as weights. 
A more complex function will naturally fit better to the data, however, increasing the 
polynomial order may lead to overfitting (Hawkins 2004, Friedrich 2016). A 
Chi-squared test was used in Paper II to decide the superior fit. The test rejected the 
lower order polynomial, if the results gave a p-value under 0.05 (95% confidence 
level), which indicate that the extra parameters result in a better fit without overfitting.  
In Paper III regression was performed in two separate procedures: As described in 
section 5.1.1, the LQ-model was first fitted to the dose/survival data points, and these 
parameters were used in the experimental database. Subsequently, the function in 
Equation A	 was fitted to the restricted databases to determine the single c 
parameter. If the fitting interval of c did not include 0, we regarded the RBEmin function 
to be independent on the LETd value. 
5.2 Recalculation of treatment plans 
Today in proton therapy, no treatment planning systems (TPS) includes a standard 
option to estimate the LETd or the RBE-weighted dose (DRBE) with a variable RBE 
model. In order to quantify the RBE and DRBE for clinical treatment plans we used the 
FLUKA Monte Carlo code (Böhlen et al. 2014, Ferrari et al. 2005) to estimate the RBE. 
In Paper I, we compared the RBE-modelled dose for all phenomenological models, 
both in a water phantom and for clinical cases. In Paper II, we compared our own 
developed RBE-model to the models by Wedenberg et al. (2013) and McNamara et al. 
(2015) for a SOBP in a water phantom. 
All treatment plans were created in a clinical TPS (Varian Eclipse™ (Varian Medical 
Systems, Palo Alto, California)) and imported into the FLUKA/Flair architecture by a 
locally developed software solution (Fjæra et al. 2017). All the SOBP plans were 
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optimised with a single field to give a uniform dose across the target volume, while the 
patient plans were planned with two treatment fields.  
Within the FLUKA architecture, the CT images of the patient were imported and 
transformed to the FLUKA geometry with Flair, a graphical user interface software for 
FLUKA. The system had previously been calibrated to the Eclipse™ TPS to give an 
acceptable and comparable proton range for every relevant energy and material (Fjæra 
et al. 2017).  In FLUKA, so-called subroutines are used for complex simulations not 
achievable through standard source definition and scoring. Two subroutines were 
modified to calculate the dose.  
First, the source subroutine was adapted to simulate all the pencil beams with the 
internal distribution. Based on their weighting, the properties (energy, spot position, 
beam focus) of each primary proton was randomly sampled from the distribution of 
pencil beams. Each pencil beam was defined by its position and energy. The SOBP 
plans were calculated with 100 million primary protons, while each field of the clinical 
plans were simulated with 50 million protons. 
Further, a fluscw (FLUence SCoring Weight) subroutine was also used to score the 
dose to water (Dw), the LETdw and the DRBE. This was done in an identical grid to the 
scoring matrix of the prefabricated plan made by the TPS, thus keeping the same 
resolution. For a single particle, the fluence-like quantity of a single particle can be 
estimated by finding the infinitesimal length of the particle trajectory, divided by 
infinitesimal volume (Papiez and Battista 1994):  
The subroutine can modify the spatial scoring, by weighting the spatial fluence (W) of 
a particle i in the individual voxel by a user defined quantity (W), before it is summed 









For every voxel, the total scored quantity will be summed over for all particles i passing 
through. To obtain dose to water for each particle i, Equation (5.4 was modified to 
score: 
where  is the density of water, LETiw is the LET to water of particle i and W is the 
“fluence-like” quantity scored by the traversing particles. The LETw value of the 
particle traversing the voxel was obtained with the GETLET() function, included in 
FLUKA. The function is dependent the particle type, energy and type of material, and 
it outputs the LET by a lookup table. In our work, we have used the LET from all 
particles when calculating the full physical dose. Equation (5.5) was also modified to 
only score the dose to water by protons and deuterium ions, ignoring heavier ions and 
other particles.   
Scoring of LETdw was performed in two steps. First the dose to water times the LETdw 
was scored: 
The division of LETdwDw by Dw to find LETdw was done subsequently in an offline 
Python script (Fjæra et al. 2017). For all pure proton RBE models, we only estimated 
the dose deposited and LET value of protons, deuterium ions and tritium ions, both 
primary and secondary. For all LETd based models, this quantity was used to find the 
RBEmax and the RBEmin for every model. Subsequently, these quantities were used 
together with the spatial distributed Diw values to find the RBEi values by Equation 
	Z.  
















For RBE models based on the energy and LET spectrum, the ./RS, and ./RWX 
quantities had to be calculated online during the simulations. This was also done by the 
fluscw subroutine by finding the quantities multiplied by the dose and dividing with the 
dose offline. The quantities were found based on Equations (3.12) and (3.13): 
and 
where bRS, and bRWX are the biological weighting functions defined by each RBE 
model.  
All these quantities are scored in a volume, estimated from the track length of the 
particles in a grid of voxel volumes. While for the SOBP examples, we scored the full 
LET spectrum (d(L)) directly from planes perpendicular to the beam axis with the 
USRYIELD (USeR defined YIELD) scoring card. The spectrum was defined as a 
histogram of 1000 bins, logarithmic spaced between 0.01 keV/μm and 100 keV/μm for 
every 0.5 mm along the depth of the phantom. The LETd and the RBE and DRBE of the 
models where all found in a MATLAB analysis architecture offline, subsequent the 
simulations. 
  



















6. Summary of Results 
6.1 Paper I: Comparison of phenomenological models 
Paper I include a wide comparison of all phenomenological models for the proton RBE 
that were published before November 2017, as well as two plan-based models leading 
to an investigation of in total 14 models. For all models the RBE values increased with 
increasing LETd value and depth, as seen in Figure 10. The extent of the RBE varied 
with the models and the RBE-weighted doses ranged, in some extreme cases, from 
28-52 Gy(RBE). This indicates that the selection of RBE model in a dose planning 
study is highly significant.  
 
Figure 10: A depth distribution of a SOBP in water. The physical dose is 
shown by the black line, corresponding to the left y-axis and the estimated 
RBE values from all models are shown by the coloured lines corresponding 
to the right y-axis.  
The differences in RBE could be traced back to the fundamental definition of the RBE 
model functions, RBEmax and RBEmin. The comparison showed that the functions 
mainly diverged by three major reasons: the experimental database of the model, the 
dependency assumptions of the model functions and the regression technique. The 
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model databases varied with respect to the distribution and range of LETd values and 
reference radiation fractionation sensitivity ((α/β)x). The model functions also varied 
in their different dependencies, based on the assumptions made by the model authors. 
This is the main reason why some models are made dependent on the (α/β)x value, 
while other models estimate a constant RBE for all tissue types. Lastly, the regression 
techniques also differed, mainly as some models used weighted regression with respect 
to the experimental uncertainty, such that experiments with low uncertainty are 
preferred over the other. Most models did, however, not include the uncertainties in the 
LQ-model parameters and used unweighted regression. 
6.2 Paper II: LET spectra based model 
Two of the models covered in the model study in Paper I (Rørvik unweighted and 
Rørvik weighted) were developed in Paper II. All phenomenological RBE models for 
protons developed up to the time of writing had assumed that the RBE-LET 
relationship was linear, an assumption we wanted to test. The paper introduces the 
mathematical formalism to incorporate the LET spectrum in phenomenological 
models, which could also be used in future models. In our literature search, we found 
85 monoenergetic experiments fulfilling our database constraints. The statistical test 
determined which of the five polynomials fitted to the database gave the best fit.  
The results showed that the relationship might be non-linear if the database was 
weighted relative to the measurement uncertainty with a quartic function as shown in 
Figure 11. The non-linear shape of the weighted RBEmax function is relatively flat until 
10 keV/μm, where the function increases drastically. This means in practice that 
monoenergetic beams with LETd around 5-10 keV/μm will give a relatively low RBE 
value, while a proton beam with many energies with similar LETd values typically 
found at the end of a poly-energetical SOBP, would give higher values. If all the 
experiments in the database were instead considered equal and an unweighted method 
was applied, RBEmax would be linear. 
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Figure 11: The experimental database used in the modelling shown in grey 
and the superior polynomial. The expression used in this figure 
((α/β)x(RBEmax - 1)) is a substitute for the RBEmax value, independent on the 
(α/β)x value of the experiments, enabling 2D illustration and analysis of the 
LET dependency. 
For all clinically relevant LETd values, the unweighted method gave a higher RBEmax 
value compared to the weighted method. In the SOBP example included in the paper, 
the weighted model gave relatively similar RBE values to models made by Carabe et 
al. (2012), McNamara et al. (2015) and Wedenberg et al. (2013), with a mean RBE of 
1.14 across the SOBP, while the unweighted gave a significant higher value of 1.22. 
6.3 Paper III: The dose dependency of RBEmin  
Paper III address the issue of creating a phenomenological model from a database of 
multiple experiments from different publications and connecting it to the variation in 
RBEmin by modifying the database constraints. The resulting variation in the RBEmin 
function can be seen in Figure 12, where the c value is the first order coefficient in 
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Equation A	. In those cases where c equals 0, the RBEmin function is considered 
constant, which is seen in the figure for high Dη values i.e. high minimum dose in the 
restricted database.  
 
Figure 12: The evolution of the c parameter, the first order coefficient of the 
LETd dependent RBEmin function. The Dη value correspond to the minimum 
dose of the restricted database. As seen, the c parameter decreases with 
increasing minimum dose, until around 2 Gy. 
Our results for both weighted and unweighted regression revealed the RBEmin to be 
constant for databases with high minimum doses, i.e. 2 Gy or higher. By including low 
dose data in the LQ-model regression, the RBEmin can be regarded as variable and 
increasing with increasing LETd value, as seen in Figure 12. A database based on a low 
minimum dose will then give an RBEmin of 1.4±0.1 for a LETd value around of 
5 keV/μm, while databases with only high dose data (> 2 Gy) gave an RBEmin of 
1.0±0.1. None of our restricted databases gave a decreasing RBEmin with increasing 
LETd, in contrary to some of the phenomenological and mechanistic RBE models. 




The published phenomenological models deviate in the RBE-weighted dose 
estimations. As we have shown, the models vary in the definition of the RBEmax and 
RBEmin functions, which originate from different decisions in the construction of 
databases, model assumptions and regression techniques. The variations in the 
databases can be seen by the database distribution illustrations shown in Paper I and 
the effect of database variations are also demonstrated in the RBEmin function with 
variable minimum dose in Paper III. The great variation in the estimated RBE-weighted 
doses indicate that it is not irrelevant which model that is chosen in a dose planning 
study. These results indicate that users of RBE models should make their choice of 
model based on the underlying database and assumptions, suitable to the specific use.  
The statistical analysis in Paper II indicate that the LET-RBEmax relationship is 
non-linear. This is in contrast to the established and recognised linear dependency 
assumed and applied in most proton RBE models (Paganetti 2015). Simultaneous to 
the publication of Paper II, Mairani et al. also tested this assumption (Mairani et al. 
2017). The statistical analysis of their work did, however, conclude that a linear 
dependency was sufficient. Mairani et al. used the same experimental publications as 
was used in the database applied in the model by Wedenberg et al. (2013), however, 
they also included experiments with LETd value above 30 keV/μm, adding 6 
experiments to the database up to 37.8 keV/μm. Our differences in the conclusions 
could be traced back to differences in the database construction. As shown in Paper I, 
the database in our work was significantly greater, with 85 experiments. Specially, our 
database also included the 24 experiments done by Guan et al. (2015a), which showed 
a clear non-linear LET-RBEmax relationship. The experiment was reproduced at another 
location, also showing indications of a non-linear LET-RBEmax relationship (Patel et 
al. 2017).  
The investigation in Paper II expanded the use of LET spectrum as an input for 
phenomenological models. Since the publication of the paper, Grün et al. have 
investigated the use of LET spectrum instead of the LETd value in the Local Effect 
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Model (LEM) (Grün et al. 2019). The LEM model has a clear non-linear RBEmax 
function, with a super linear dependency around 5 keV/μm, in agreement with our  
weighted model. Grün et al conclude that a model cannot be based on the LETd value 
if there is a clear non-linear dependency, this should also be true for our 
phenomenological approach.   
The uncertainty in the RBE value can be lowered by gaining more knowledge and 
creating better and more precise models. The work done in this thesis, by including the 
full LET spectrum or the dose dependency of the experimental data, might be a 
stepping stone for the creation of other novel models, increasing the precision of the 
RBE estimations. 
7.1 Experimental databases 
For our modelling work in Paper II and III, we collected data from multiple 
experimental groups and arranged them together in a large database with different 
experiments. The creation of databases from different papers and labs could be 
problematic, as the various experiments have different setups and protocols. 
Differences in the biological lab work, such as the chemicals used and cell counting 
methods applied might also cause a difference between the experiments (Guan et al. 
2015a). The publications may include and report different errors or correct the 
experiments for different effects (Paganetti 2014). Recently, two guides on reporting 
of experimental data have been published, which could contribute to more coherent 
methods in future experiments (Paganetti et al. 2019b, Durante et al. 2019). 
For the work in this thesis, experiments executed with a SOBP beam or laser 
accelerated protons were excluded, as these result in a wide LET spectrum for each 
radiation quality of the experiments. In Paper II, we practically assumed that the LET 
spectra for all our experiments were very narrow, such that they formed a perfect delta 
function around the LETd value. This assumption could lead to inaccuracies in the 
modelling, especially for low energetic protons with high LETd value from a degraded 
high energy beam, as the range straggling effect widen the spectrum (Guan et al. 
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2015a). Additionally, some inconsistencies in the LETd value could be caused by 
different LET estimation methods, as some groups have only found the LET value from 
analytical models based on the remaining range or energy (Belli et al. 1993), while 
other have found this from comprehensive Monte Carlo calculations (Dahle et al. 
2017). A longer discussion on the estimation and reporting of LET value is given in 
section 7.4. 
The regression of the LQ-model could also cause variations, if it is fitted to the linear 
or logarithmic survival data, or whether it is done with a weighted or unweighted 
regression technique, as we investigated in Paper III, illustrated in Appendix A1 of the 
paper. In this paper, the associated interlaboratory error was minimised, as we fitted 
the LQ-model directly to the dose-survival data in a coherent manner. It could be 
debated that our unweighted regression to the logarithmic data is suboptimal compared 
to weighted regression, however, it was impossible to extract the uncertainties from the 
various experiments. 
7.2 Assumptions made for RBEmax and RBEmin 
The general dependencies of the RBEmax and RBEmin functions are determined by the 
model authors before fitting to the database. Ideally, the models should be as 
independent of the authors as possible to minimise the impact of researcher bias. This 
can be done by introducing multiple assumptions and let statistical analysis decide 
which assumptions that best describe the database, as was done in Paper II and other 
models (Mairani et al. 2017, Wedenberg, Lind, and Hårdemark 2013).  
For paper III we only included a linear LET dependency of the RBEmin function since 
our goal was to test the common assumption of a constant RBEmin, independent of the 
LETd value. In this work, we excluded an (α/β)x dependency on RBEmin by only 
including experiments with low (α/β)x values in our database. From the analysis in 
Paper I, the (α/β)x dependency of RBEmin deviated for the different models, either 
linearly dependent on the (α/β)x value (Peeler 2016), the square root of the (α/β)x value 
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(McNamara, Schuemann, and Paganetti 2015) or the inverse of the (α/β)x value (Carabe 
et al. 2012). The (α/β)x dependency of RBEmin should therefore be investigated further.  
7.3 Regression techniques 
In Paper I, we revealed that model functions were usually created by regression analysis 
of fitting functions with free variables, either by unweighted regression or weighted 
regression where the variations in uncertainties in the database are considered. For our 
own model in Paper II and the analysis in Paper III, we used both regression methods. 
As shown in Figure 11 and by the regression results in Paper II, the choice of method 
has a significant impact. Generally speaking, one would assume that the weighted 
technique would give the best representation of the database. Weighted regression can 
be beneficial when the experimental database is unequally sampled, since it can reduce 
the bias due to outliers with large uncertainties. This is given under the assumption that 
there is a coherent reporting of the uncertainty in experiments, which is not the case in 
the existing experiments (Paganetti et al. 2019b).  
It is also possible to create RBEmax and RBEmin functions by other methods than 
statistical regression. As shown in Paper I, Belli et al. created the functions by linear 
interpolations in between the experimental data points (Belli, Campa, and Ermolli 
1997). Mairani et al. also tested an alternative to the RBEmin function by having a 
running average (Mairani et al. 2017). Machine learning techniques could also be 
applied to find dependencies in the database. If full LET spectrum data extracted from 
the experiments will be reported in the future, as discussed in recent reviews (Durante 
et al. 2019, Paganetti et al. 2019b), spectral unfolding techniques could alternatively 
be used to find the best fitting model functions (Reginatto 2010). As our investigations 
in Paper I shows, most models can be described by simple functions with one to four 
coefficients. However, the model by Belli et al. (1997) is an noticeable exeption, as it 
is defined by a table to find the corresponding RBEmax and RBEmin values for a given 
energy. The use of tables instead of explicit functions is already common for 
mechanistic models (Stewart et al. 2018), and it could also be applied in new 
phenomenological models.  
 57 
7.4 Software implementations  
Over the recent years, multiple Monte Carlo based software solutions have been 
developed with the possibility to recalculate patient plans with biological dose 
estimation (Böhlen et al. 2014, Ferrari et al. 2005, Polster et al. 2015). We used the 
FLUKA Monte Carlo code to estimate the dose and RBE in this thesis, as it enables a 
wide range of possibilities and ability to score various quantities. Other software 
architectures have been developed to specifically estimate the LETd and RBE 
distribution of a proton plan. Some of these implementations are based on fast and 
simplified Monte Carlo algorithms (Ödén, Eriksson, and Toma-Dasu 2017a, Kohno et 
al. 2019), while other are based on analytical LETd algorithms (Choi et al. 2018, Wieser 
et al. 2017). Even though they are faster than a full Monte Carlo simulation, the user 
should be aware of the limitations, as precision is traded against calculation time. With 
regard to our work in Paper I, only full Monte Carlo software like FLUKA is able to 
produce the full LET spectra today, which is needed for the input. Creating an 
analytical algorithm for the full LET spectrum for a TPS should be feasible, based on 
simplified rules for range straggling and nuclear interactions.  
Spectrum based models need to be implemented directly into the software and 
calculated online during the dose calculation. In practice, this means that model 
functions need to be defined before the calculation, together with all relevant (α/β)x 
values and variations of the model coefficients. Offline calculation only estimates the 
pure physical quantities (dose and LET values) and offer the possibility to adjust the 
physical values after the patient plan have been calculated. This can be convenient for 
analysis of various models’ coefficients and some robust planning procedures. 
Furthermore, typical offline analysis of the uncertainty of RBE models similar to the 
work by Ödén et al (2017b) is not straight forward for spectrum based models. 
In our calculations, we estimated the LET value with two different methods, either 
volumetrically or across boundaries (Guan et al. 2015b). Ideally, the LET should be 
scored in a grid equal to the dose grid, so the LET value needs be scored volumetrically. 
Volumetric scoring also enables more precise scoring from multiple fields with 
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different angles. Only the LET to water was scored in this work, instead of LET to 
tissue. Dose to water is standardised to report in radiotherapy (Liu, Keall, and Hendee 
2002). It is therefore natural that the equivalent is also reported for LET, even though 
it can differ significantly from LET to tissue, and might exclude some effects, 
especially within the lungs and bone (Wilkens, Jan J. and Oelfke 2004).  
In our calculations, we used the LET value from only protons, both primary and 
secondary protons, which is typical for other studies as well (Yepes et al. 2019, 
Granville and Sawakuchi 2015, Wilkens and Oelfke 2003). However, other secondaries 
could also affect the LET value (Grassberger and Paganetti 2011). According to a 
recent study, the variation from including or excluding heavier ions might be large and 
could double the LETd value (Grzanka, Ardenfors, and Bassler 2018). A method to 
include the effect of various particles into a single RBE estimate have been integrated 
in the phenomenological model by Mairani (Mairani et al. 2017, 2016a, 2016b) or for 
many mechanistic models (Stewart et al. 2018). 
7.5 Suggestions to experimental reporting 
The reported quantities in phenomenological models should ideally be similar, both for 
the reported experimental data and application to clinical cases. The dose and LET 
value of the experiment should be calculated in the same manner as the use in patient 
calculations, with the same definitions of the scored LET, with regard to the material 
and energy cut off value. The dose levels of experiments should also be covering a 
greater range of values, especially including low doses under 1 Gy, as these values are 
clinically relevant for OARs in normal fractionated proton plans. As we showed in 
Paper III, many experiments are, however, lacking data for dose levels under 1 Gy. 
As recently suggested by the work groups on RBE experiments (Durante et al. 2019, 
Paganetti et al. 2019b), the full LET spectrum from experiments could be reported. 
Some recent articles have included experiments and analysis of wide and narrow 
spectra with the same LETd value (Chaudhary et al. 2014, Howard et al. 2018, Grün et 
al. 2019, Dahle et al. 2017), however, all of these only give an illustration of the spectra. 
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As it is not possible or convenient to report full spectra numerically in conventional 
articles, it could be possible that the data is uploaded directly into an online database, 
like the Particle Irradiation Data Ensemble (Friedrich et al. 2013). This could both help 
create more precise models and verify the precision of existing models. Further, such 
a database could also include all the individual dose-survival data points from the 
experiment including uncertainties, not only the commonly reported α and β values. 
This will aid projects like the work in Paper III, as we had to extract data from figures, 
instead of the directly measured data. It could also enable easier adaptation and 
development of the novel global fitting method, as described by Abolfath et al. (2017). 
This method fit both the RBEmax and RBEmin functions simultaneous and directly to the 
experimental survival data in one single regression, instead of conventional approach 
of one regression of the LQ-model followed by another fit for each of the two model 
functions.  
7.6 The effect of variable RBE 
A variable RBE can be beneficial, if the increased effect of protons is located at the 
tumour location. This aspect could be quantified by the ratio of RBE-weighted dose to 
the tumour and the normal tissue, i.e. the biological effective dose ratio (BEDR) 
(Holzscheiter et al. 2006, Grün et al. 2015). A higher BEDR value correspond to a 
better treatment effect and is preferred for optimal treatment. An increased BEDR is 
the reason why heavier ions, like helium ions and carbon ions are considered extra 
effective compared to protons, as shown in a comparison by Jäkel (2006, 2009).  
From Paper I we see that most models estimate an increasing RBE value with 
increasing LETd value, decreasing (α/β)x value and decreasing physical proton dose, 
similar to the conclusions given by Paganetti in a review paper of experimental data 
(Paganetti 2014). The LETd value is higher in the tumour than the normal tissue in front 
of the tumour, leading to a generally greater BEDR value. However, this is only valid 
with the assumption of similar (α/β)x for the tumour and normal tissues. With higher 
(α/β)x for the tumour, the predicted BEDR will be reduced. The BEDR will therefore 
be highly case specific.  
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7.7 Is an RBE of 1.1 still an appropritate assumption? 
In this work, we have only reanalysed existing experimental data in the literature. Most 
of the cells included in our analysis in Paper II and III are from Chinese hamsters and 
other animals (Paganetti 2014). This could introduce an uncertainty in biological 
response, as these cell lines could divert from the spontaneous human tumours.  
Phenomenological models could then be based solely on cultivated normal cells from 
human tissue, estimating the RBE for normal tissue or solely on human cancer cells for 
the RBE to the target (Hall et al. 1988, Belli et al. 2000).  
In vitro experiments and analysis of cell irradiations is perhaps not enough alone to 
challenge the established assumption of a constant RBE of 1.1. There should at least 
be relevant in vivo data, from irradiation of rats and mice, proving that there is a 
non-negligible variable RBE in proton therapy that needs to be accounted for. A 
meta-analysis of existing in vivo data from 2002 found no significant variation in the 
RBE and ratified the use of a constant RBE of 1.1 (Paganetti et al. 2002). However, 
more recent experiment work on animal models, irradiated with multiple LETd values, 
have indeed indicated that there is a correlation between increased LET and RBE 
(Sørensen et al. 2017, Saager et al. 2018, Szabó et al. 2018).  
Although a variable RBE has been seen in preclinical experiments, there has not been 
documented an increased rate of clinical complications in treated patients which can be 
traced back to an increased RBE above 1.1 (Lühr et al. 2018, Paganetti 2015). This still 
advocates for keeping a constant RBE in clinical protocols (Paganetti 2015). However, 
a recent study investigating MR images of the brain post treatment, found a correlation 
between increased LET values and image changes (Peeler et al. 2016). Another study 
also found image changes in the chest wall of lung, which could be related to increased 
LET values (Underwood et al. 2018). The clinical consequences for the patients with 
these image changes are still unknow, and longer follow up time is needed to determine 
if they lead to complications. Nevertheless, proton therapy clinics should still consider 
the potential risk in treatment planning by carefully selecting the treatment fields to 
spare OARs of possible high RBE values (Paganetti et al. 2019b). 
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8. Conclusion 
The transfer from conventional radiotherapy with photons to modern radiotherapy with 
protons is not only a change in the physical dose deposition, but also in the biological 
response of the ionising radiation. The RBE concept enables easy transition of existing 
photon therapy protocols to be used in proton therapy. In this thesis, possible 
alternatives to the generic use of constant RBE have been investigated, through analysis 
and development of phenomenological models from cell survival databases. 
Large deviations between different RBE models were found in the estimations of the 
RBE-weighted dose. The dissection and parameterisation of the models traced the 
differences in the estimation to the variations in database distributions of (α/β)x values 
and LETd values, model assumptions and regression technique.  
The LET dependencies for both RBEmax and RBEmin were further investigated. To 
explore non-linear models, the full LET spectrum was implemented as input in 
phenomenological RBE models. Based on a large database of all published cell survival 
experiments with monoenergetic protons and statistical analysis, a weighted regression 
analysis indicated that the LET-RBEmax relationship is indeed non-linear, contrary to 
other established models. By extracting the dose-survival data from a large database of 
experiments on late responding cells, the LETd-RBEmin relationship was studied with a 
novel two step regression analysis method. The examination of restricted databases of 
experiments with a minimum dose at 1 Gy or lower indicated that the RBEmin function 
increases with increasing LETd value.   
Overall, the thesis shows similarities and differences between existing 
phenomenological RBE models for proton therapy and show multiple possibilities of 
developing novel model by reanalysing existing experimental data that can challenge 
common assumptions in the RBE dependencies and give a better understanding of the 
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